| International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI AS Ruppert, JG Dixon, G Salles, A Wall, D Cunningham, V Poeschel, ... Blood, The Journal of the American Society of Hematology 135 (23), 2041-2048, 2020 | 299 | 2020 |
| Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials C Casulo, JG Dixon, J Le-Rademacher, E Hoster, HS Hochster, ... Blood, The Journal of the American Society of Hematology 139 (11), 1684-1693, 2022 | 119 | 2022 |
| CODEL: phase III study of RT, RT+ TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design KA Jaeckle, KV Ballman, M Van Den Bent, C Giannini, E Galanis, ... Neuro-oncology 23 (3), 457-467, 2021 | 94 | 2021 |
| Stereotactic radiosurgery with or without whole-brain radiation therapy for limited brain metastases: a secondary analysis of the North Central Cancer Treatment Group N0574 … TM Churilla, KV Ballman, PD Brown, EL Twohy, K Jaeckle, E Farace, ... International Journal of Radiation Oncology* Biology* Physics 99 (5), 1173-1178, 2017 | 84 | 2017 |
| Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: an individual patient–level analysis of multiple randomized … Q Shi, N Schmitz, FS Ou, JG Dixon, D Cunningham, M Pfreundschuh, ... Journal of Clinical Oncology 36 (25), 2593-2602, 2018 | 81 | 2018 |
| Tissue-specific SMARCA4 binding at active and repressed regulatory elements during embryogenesis C Attanasio, AS Nord, Y Zhu, MJ Blow, SC Biddie, EM Mendenhall, ... Genome research 24 (6), 920-929, 2014 | 77 | 2014 |
| Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34 640 patients in the ACCENT database AD Wagner, A Grothey, T Andre, JG Dixon, N Wolmark, DG Haller, ... JNCI: Journal of the National Cancer Institute 113 (4), 400-407, 2021 | 72 | 2021 |
| A phase 1 and randomized, placebo‐controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group … E Galanis, SK Anderson, EL Twohy, XW Carrero, JG Dixon, DD Tran, ... Cancer 125 (21), 3790-3800, 2019 | 71 | 2019 |
| Lack of caudal-type homeobox transcription factor 2 expression as a prognostic biomarker in metastatic colorectal cancer BY Zhang, JC Jones, AM Briggler, JM Hubbard, BR Kipp, DJ Sargent, ... Clinical colorectal cancer 16 (2), 124-128, 2017 | 57 | 2017 |
| Validation of POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma: results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH … C Casulo, J Le-Rademacher, J Dixon, G Salles, E Hoster, M Herold, ... Blood 130, 412, 2017 | 43 | 2017 |
| Clinicopathological and molecular characteristics of early-onset stage III colon adenocarcinoma: an analysis of the ACCENT database Z Jin, JG Dixon, JM Fiskum, HD Parekh, FA Sinicrope, G Yothers, ... JNCI: Journal of the National Cancer Institute 113 (12), 1693-1704, 2021 | 35 | 2021 |
| Intra‐CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases KA Jaeckle, JG Dixon, SK Anderson, A Moreno‐Aspitia, G Colon‐Otero, ... Cancer medicine 9 (21), 7935-7942, 2020 | 22 | 2020 |
| Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer. A Chawla, Q Shi, AH Ko, S Beg, AM Varghese, SW Behrman, ... Journal of Clinical Oncology 41 (16_suppl), TPS4204-TPS4204, 2023 | 18 | 2023 |
| Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter … JN Sarkaria, KV Ballman, SH Kizilbash, EP Sulman, C Giannini, ... Journal of Clinical Oncology 40 (16_suppl), 2001-2001, 2022 | 15 | 2022 |
| Reevaluating disease-free survival as an endpoint vs overall survival in stage III adjuvant colon cancer trials J Yin, ME Salem, JG Dixon, Z Jin, R Cohen, A DeGramont, E Van Cutsem, ... JNCI: Journal of the National Cancer Institute 114 (1), 60-67, 2022 | 10 | 2022 |
| Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 … KA Jaeckle, SK Anderson, EL Twohy, JG Dixon, C Giannini, R Jenkins, ... Journal of neuro-oncology 143, 573-581, 2019 | 10 | 2019 |
| Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy+/-biologics: An updated surrogacy … Q Shi, A De Gramont, JG Dixon, J Yin, E Van Cutsem, J Taieb, SR Alberts, ... Journal of Clinical Oncology 37 (15_suppl), 3502-3502, 2019 | 8 | 2019 |
| Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials C Casulo, JG Dixon, FS Ou, E Hoster, BA Peterson, HS Hochster, P Brice, ... Blood Advances 5 (6), 1737-1745, 2021 | 7 | 2021 |
| Association of sex and adverse events (AEs) of adjuvant chemotherapy (ACT) in early stage colon cancer (CC): A pooled analysis of 28,636 patients (pts) in the ACCENT database. AD Wagner, A Grothey, T Andre, J Dixon, N Wolmark, DG Haller, ... Journal of Clinical Oncology 36 (15_suppl), 3603-3603, 2018 | 7 | 2018 |
| Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic … FS Ou, JM Hubbard, PM Kasi, J Dixon, E Van Cutsem, L Saltz, HJ Schmoll, ... Journal of Clinical Oncology 35 (15_suppl), 3535-3535, 2017 | 6 | 2017 |
